Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.94% | 59.17% | -- | -- | -- |
| Total Depreciation and Amortization | -38.93% | -19.58% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.53% | -188.15% | -- | -- | -- |
| Change in Net Operating Assets | -611.88% | -370.14% | -- | -- | -- |
| Cash from Operations | -83.70% | -51.25% | -- | -- | -- |
| Capital Expenditure | 100.00% | -199.04% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 114.33% | -149.04% | -- | -- | -- |
| Total Debt Issued | 248.18% | -- | -- | -- | -- |
| Total Debt Repaid | -93.40% | -93.40% | -- | -- | -- |
| Issuance of Common Stock | 72.14% | 129.14% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 172.07% | 177.26% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,523.33% | 1,343.89% | -- | -- | -- |